MA39019A1 - Acétate de 4-{4-[(1e)-4-(2,9-diazaspiro[5.5]undéc-2-yl)but-1-én-1-yl]-2-méthylbenzyl}-5-(propan-2-yl)-1h-pyrazol-3-yl-bêta-d-glucopyranoside - Google Patents
Acétate de 4-{4-[(1e)-4-(2,9-diazaspiro[5.5]undéc-2-yl)but-1-én-1-yl]-2-méthylbenzyl}-5-(propan-2-yl)-1h-pyrazol-3-yl-bêta-d-glucopyranosideInfo
- Publication number
- MA39019A1 MA39019A1 MA39019A MA39019A MA39019A1 MA 39019 A1 MA39019 A1 MA 39019A1 MA 39019 A MA39019 A MA 39019A MA 39019 A MA39019 A MA 39019A MA 39019 A1 MA39019 A1 MA 39019A1
- Authority
- MA
- Morocco
- Prior art keywords
- diazaspiro
- glucopyranoside
- undec
- methylbenzyl
- pyrazol
- Prior art date
Links
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 title 1
- -1 2,9-diazaspiro [5.5] undec-2-yl Chemical group 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/20—Spiro-condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D309/06—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Cette invention concerne un composé de formule i ou un hydrate de celui-ci, utile pour le traitement du diabète.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361901488P | 2013-11-08 | 2013-11-08 | |
| PCT/US2014/063161 WO2015069541A1 (fr) | 2013-11-08 | 2014-10-30 | Acétate de 4-{4-[(1e)-4-(2,9-diazaspiro[5.5]undéc-2-yl)but-1-én-1-yl]-2-méthylbenzyl}-5-(propan-2-yl)-1h-pyrazol-3-yl-bêta-d-glucopyranoside |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA39019A1 true MA39019A1 (fr) | 2017-04-28 |
Family
ID=51982747
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA39019A MA39019A1 (fr) | 2013-11-08 | 2014-10-30 | Acétate de 4-{4-[(1e)-4-(2,9-diazaspiro[5.5]undéc-2-yl)but-1-én-1-yl]-2-méthylbenzyl}-5-(propan-2-yl)-1h-pyrazol-3-yl-bêta-d-glucopyranoside |
Country Status (35)
| Country | Link |
|---|---|
| US (1) | US9573970B2 (fr) |
| EP (1) | EP3066108B1 (fr) |
| JP (1) | JP6197113B2 (fr) |
| KR (1) | KR101858881B1 (fr) |
| CN (1) | CN105705509B (fr) |
| AP (1) | AP2016009180A0 (fr) |
| AR (2) | AR098670A1 (fr) |
| AU (1) | AU2014347065B2 (fr) |
| CA (1) | CA2925128C (fr) |
| CL (1) | CL2016000791A1 (fr) |
| CR (1) | CR20160165A (fr) |
| CY (1) | CY1121096T1 (fr) |
| DK (1) | DK3066108T3 (fr) |
| DO (1) | DOP2016000067A (fr) |
| EA (1) | EA028801B1 (fr) |
| ES (1) | ES2703944T3 (fr) |
| HR (1) | HRP20182061T1 (fr) |
| IL (1) | IL244899B (fr) |
| JO (1) | JO3485B1 (fr) |
| LT (1) | LT3066108T (fr) |
| MA (1) | MA39019A1 (fr) |
| MX (1) | MX368174B (fr) |
| MY (1) | MY192242A (fr) |
| NZ (1) | NZ718118A (fr) |
| PE (1) | PE20160884A1 (fr) |
| PH (1) | PH12016500851B1 (fr) |
| PL (1) | PL3066108T3 (fr) |
| PT (1) | PT3066108T (fr) |
| RS (1) | RS58050B1 (fr) |
| SI (1) | SI3066108T1 (fr) |
| SV (1) | SV2016005190A (fr) |
| TN (1) | TN2016000112A1 (fr) |
| TW (1) | TWI655198B (fr) |
| UA (1) | UA118767C2 (fr) |
| WO (1) | WO2015069541A1 (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES3011733T3 (en) * | 2015-02-13 | 2025-04-08 | Transgene | Immunotherapeutic vaccine and antibody combination therapy |
| JP2020523394A (ja) * | 2017-06-12 | 2020-08-06 | リグナメッド・エルエルシーＬｉｇｎａｍｅｄ，Ｌｌｃ | （ｓ，ｓ）−セコイソラリシレシノールジグルコシド及び（ｒ，ｒ）−セコイソラリシレシノールジグルコシドの製造方法 |
| CN110054657B (zh) * | 2018-01-18 | 2021-06-29 | 亚宝药业集团股份有限公司 | 吡喃葡萄糖取代的吡唑化合物及其制备方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE264337T1 (de) | 1999-08-31 | 2004-04-15 | Kissei Pharmaceutical | Glucopyranosyloxypyrazol-derivate, diese enthaltende arzneimittel und zwischenprodukte zu deren herstellung |
| CA2438593C (fr) | 2001-02-26 | 2010-09-21 | Kissei Pharmaceutical Co., Ltd. | Derives de glycopyranosyloxypyrazole et utilisation medicinale de ceux-ci |
| US7217697B2 (en) | 2001-05-30 | 2007-05-15 | Kissei Pharmaceutical Co., Ltd. | Glucopyranosyloxypyrazole derivative medicinal composition containing the same medicinal use thereof and intermediate therefor |
| ZA200501094B (en) * | 2002-08-08 | 2006-10-25 | Kissei Pharmaceutical | Pyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof |
| PL213095B1 (pl) * | 2002-08-08 | 2013-01-31 | Kissei Pharmaceutical | Pochodna pirazolu, kompozycja farmaceutyczna, srodek do leczenia lub hamowania choroby i zastosowanie pochodnej pirazolu |
| JP2004137245A (ja) | 2002-08-23 | 2004-05-13 | Kissei Pharmaceut Co Ltd | ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体 |
| DE102004028241B4 (de) | 2004-06-11 | 2007-09-13 | Sanofi-Aventis Deutschland Gmbh | Neue Fluorglykosidderivate von Pyrazolen, diese Verbindungen enthaltende Arzneimittel und Herstellung dieser Arzneimittel |
| TW200812995A (en) * | 2006-05-19 | 2008-03-16 | Taisho Pharmaceutical Co Ltd | C-phenyl glycitol compound |
| EP2228378B1 (fr) | 2007-12-27 | 2015-09-09 | Kissei Pharmaceutical Co., Ltd. | Monosébacate d'un dérivé de pyrazole |
| SG173801A1 (en) | 2009-02-23 | 2011-09-29 | Taisho Pharmaceutical Co Ltd | 4 -isopropylphenyl glucitol compounds as sglt1 inhibitors |
| KR20120091174A (ko) | 2009-10-02 | 2012-08-17 | 사노피 | 골질환 치료제의 제조를 위한 ｓｇｌｔ-1/ｓｇｌｔ-2 억제제 활성을 갖는 화합물의 용도 |
| US8163704B2 (en) | 2009-10-20 | 2012-04-24 | Novartis Ag | Glycoside derivatives and uses thereof |
| UA113086C2 (xx) * | 2012-05-10 | 2016-12-12 | Піразольні сполуки як інгібітори sglt1 |
-
2014
- 2014-10-24 AR ARP140104010A patent/AR098670A1/es not_active Application Discontinuation
- 2014-10-26 JO JOP/2014/0310A patent/JO3485B1/ar active
- 2014-10-27 TW TW103137067A patent/TWI655198B/zh active
- 2014-10-30 PL PL14802974T patent/PL3066108T3/pl unknown
- 2014-10-30 HR HRP20182061TT patent/HRP20182061T1/hr unknown
- 2014-10-30 MX MX2016005999A patent/MX368174B/es active IP Right Grant
- 2014-10-30 ES ES14802974T patent/ES2703944T3/es active Active
- 2014-10-30 EP EP14802974.7A patent/EP3066108B1/fr active Active
- 2014-10-30 MY MYPI2016701635A patent/MY192242A/en unknown
- 2014-10-30 LT LTEP14802974.7T patent/LT3066108T/lt unknown
- 2014-10-30 PT PT14802974T patent/PT3066108T/pt unknown
- 2014-10-30 AP AP2016009180A patent/AP2016009180A0/en unknown
- 2014-10-30 NZ NZ718118A patent/NZ718118A/en unknown
- 2014-10-30 PE PE2016000546A patent/PE20160884A1/es unknown
- 2014-10-30 MA MA39019A patent/MA39019A1/fr unknown
- 2014-10-30 DK DK14802974.7T patent/DK3066108T3/da active
- 2014-10-30 EA EA201690749A patent/EA028801B1/ru not_active IP Right Cessation
- 2014-10-30 CN CN201480060924.9A patent/CN105705509B/zh active Active
- 2014-10-30 SI SI201430941T patent/SI3066108T1/sl unknown
- 2014-10-30 UA UAA201603973A patent/UA118767C2/uk unknown
- 2014-10-30 US US15/026,427 patent/US9573970B2/en active Active
- 2014-10-30 CA CA2925128A patent/CA2925128C/fr active Active
- 2014-10-30 KR KR1020167011764A patent/KR101858881B1/ko active Active
- 2014-10-30 RS RS20181382A patent/RS58050B1/sr unknown
- 2014-10-30 WO PCT/US2014/063161 patent/WO2015069541A1/fr not_active Ceased
- 2014-10-30 JP JP2016526778A patent/JP6197113B2/ja active Active
- 2014-10-30 TN TN2016000112A patent/TN2016000112A1/en unknown
- 2014-10-30 AU AU2014347065A patent/AU2014347065B2/en active Active
-
2016
- 2016-03-17 DO DO2016000067A patent/DOP2016000067A/es unknown
- 2016-04-04 IL IL24489916A patent/IL244899B/en active IP Right Grant
- 2016-04-06 CL CL2016000791A patent/CL2016000791A1/es unknown
- 2016-04-06 CR CR20160165A patent/CR20160165A/es unknown
- 2016-05-03 SV SV2016005190A patent/SV2016005190A/es unknown
- 2016-05-06 PH PH12016500851A patent/PH12016500851B1/en unknown
-
2018
- 2018-12-12 CY CY181101334T patent/CY1121096T1/el unknown
-
2021
- 2021-11-17 AR ARP210103177A patent/AR124083A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201791002A1 (ru) | Новые соединения, модулирующие fxr (nr1h4) | |
| EA201690153A1 (ru) | Замещенные бензофуранильные и бензоксазолильные соединения и их применения | |
| EA201791017A1 (ru) | Гидроксисодержащие соединения, модулирующие fxr (nr1h4) | |
| EA201991197A1 (ru) | БЕНЗИМИДАЗОЛЬНЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ c-Kit | |
| EA201691625A1 (ru) | Ароматические гетероциклические соединения как противовоспалительные соединения | |
| CU20170057A7 (es) | Derivados de feniltriazol sustituido con hidroxialquilo | |
| MA42109A (fr) | Amides hétérocycliques utilisés en tant qu'inhibiteurs de kinase | |
| EA201990044A1 (ru) | Гетероциклические соединения в качестве антибактериальных средств | |
| PE20180024A1 (es) | Triazolopirazinonas como inhibidores de pde1 | |
| UA118444C2 (uk) | Спосіб одержання заміщених оксиранів і триазолів | |
| EA201691913A1 (ru) | Замещенные [1,2,4]триазольные и имидазольные соединения в качестве фунгицидов | |
| EA201892430A1 (ru) | Синтез индазолов | |
| EP4599830A3 (fr) | Composés d'isoxazoline destinés à être utilisés dans le traitement de la démodiose | |
| EA201691982A1 (ru) | 5,6-дизамещенные пиридин-2-карбоксамиды в качестве агонистов каннабиноидных рецепторов | |
| EA201692289A1 (ru) | Замещенные [1,2,4]триазольные и имидазольные соединения в качестве фунгицидов | |
| EA201791671A1 (ru) | 4-замещенные соединения бензоксаборола и их применение | |
| CY1122506T1 (el) | Κρυσταλλικη μορφη της ενωσης (s)-3-{4-[5-(2-κυκλοπεντυλ-6- μεθοξυ- πυριδιν-4- υλ)-[1,2,4]οξαδιαζολ-3- υλ]-2- αιθυλ-6-μεθυλ- φαινοξυ}- προπανο-1,2- διολη | |
| EA201690227A1 (ru) | Азаиндольные соединения, их получение и способы их применения | |
| MA39019A1 (fr) | Acétate de 4-{4-[(1e)-4-(2,9-diazaspiro[5.5]undéc-2-yl)but-1-én-1-yl]-2-méthylbenzyl}-5-(propan-2-yl)-1h-pyrazol-3-yl-bêta-d-glucopyranoside | |
| UA113988C2 (xx) | Спосіб стабілізації бета-напівгідрату штукатурного гіпсу | |
| MA39110B1 (fr) | Nouveau composé pour le traitement de l'hypoglycémie grave | |
| MA39108A1 (fr) | Nouveau composé pour le traitement de l'hypoglycémie sévère | |
| MA39109B1 (fr) | Nouveau composé pour le traitement de l'hypoglycémie grave | |
| PE20171259A1 (es) | Compuestos | |
| PH12016500788A1 (en) | Compounds for the treatment of diabetes and disease complications arising from same |